ClinicalTrials.gg

Program

23-valent pneumococcal capsular polysaccharide vaccine

Also written as “PPV23”, “23-valent pneumococcal polysaccharide vaccine” and “Pneumovax™ 23”.

Its studies are mostly in Pneumococcal Infections · Influenza, Human · Diphtheria · Pneumonia, Pneumococcal · Whooping Cough, led by 8 companies.

Furthest: phase 4, since Oct 6, 201416 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck50 open or runningphase 4since Oct 6, 2014Jul 3, 2007none ahead
GlaxoSmithKline40 open or runningphase 4since Feb 20, 2014Mar 24, 2006none ahead
Sinopharm20 open or runningphase 4since Jan 6, 2021Jan 6, 2021none ahead
Aimei Vacin BioPharm (Zhejiang)11 open or runningphase 3since Sep 13, 2023Sep 13, 2023none ahead
Chongqing Zhifei Biological Products10 open or runningphase 3since Feb 18, 2020Feb 18, 2020none ahead
Pfizer10 open or runningphase 4since Aug 21, 2006Aug 21, 2006none ahead
Sanofi10 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Sinovac Biotech10 open or runningphase 4since Jul 13, 2022Jul 13, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Mar 24, 2006.

  1. Aug 21, 2006Pfizer’s first study: phase 4 study in Pneumococcal InfectionsNew to PfizerPfizer · NCT00368186 · 51 enrolled · France
  2. Jul 3, 2007Merck’s first study: phase 3 study in Pneumococcal InfectionsNew to MerckMerck · NCT00496093 · 133 enrolled
  3. Sep 21, 2007Phase 3 study in Herpes ZosterMerck · NCT00535730 · 473 enrolled
  4. Dec 19, 2007Sanofi’s first study: phase 3 study in Streptococcus PneumoniaeNew to SanofiSanofi · NCT00594347 · 339 enrolled · Thailand
  5. Nov 21, 2012Phase 3 study in Pneumococcal InfectionsMerck · NCT01734239 · 102 enrolled
  6. Feb 20, 2014Phase 4 study in Whooping CoughGlaxoSmithKline · NCT02072525 · 359 enrolled · Canada
  7. Aug 14, 2014Phase 3 study in Influenza, HumanGlaxoSmithKline · NCT02218697 · 357 enrolled · Belgium, France
  8. Aug 22, 2014Phase 3 study in Pneumococcal InfectionsMerck · NCT02225587 · 400 enrolled
  9. Oct 6, 2014Phase 4 study in Pneumococcal InfectionsMerck · NCT02260882 · 243 enrolled
  10. Feb 9, 2020Phase 1 study in Healthy VolunteersGlaxoSmithKline · NCT04265911 · 126 enrolled · Japan
  11. Feb 18, 2020Chongqing Zhifei Biological Products’ first study: phase 3 study in Pneumonia, PneumococcalNew to Chongqing Zhifei Biological ProductsChongqing Zhifei Biological Products · NCT04278248 · 1,940 enrolled · China
  12. Jan 6, 2021Sinopharm’s first studies: 2 phase 4 studies in VaccinationNew to SinopharmSinopharm · NCT04701788, NCT04700618
  13. Jul 13, 2022Sinovac Biotech’s first study: phase 4 study in Influenza, HumanNew to Sinovac BiotechSinovac Biotech · NCT05471531 · 3,000 enrolled · China
  14. Sep 13, 2023Aimei Vacin BioPharm (Zhejiang)’s first study: phase 3 study in Pneumococcal InfectionsNew to Aimei Vacin BioPharm (Zhejiang)Aimei Vacin BioPharm (Zhejiang) · NCT06044077 · 1,920 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06044077Pneumococcal Infections · China3RecruitingAimei Vacin BioPharm (Zhejiang)Mar 8, 20241,920
NCT05471531Influenza, Human · China4CompletedSinovac BiotechMar 10, 20223,000
NCT04701788Vaccination · China4CompletedSinopharmDec 20, 2021331
NCT04700618Vaccination · China4CompletedSinopharmAug 22, 2021330
NCT04278248Pneumonia, Pneumococcal · China3CompletedChongqing Zhifei Biological ProductsJun 7, 20181,940
NCT04265911Healthy Volunteers · Japan1CompletedGlaxoSmithKlineNov 7, 2020126
NCT02260882Pneumococcal Infections4CompletedMerckApr 9, 2015243
NCT02225587Pneumococcal Infections3CompletedMerckJul 6, 2015400
NCT02218697Influenza, Human · Belgium, France3CompletedGlaxoSmithKlineJan 14, 2015357
NCT02072525Whooping Cough · Canada4CompletedGlaxoSmithKlineJun 2, 2015359
NCT01734239Pneumococcal Infections3CompletedMerckOct 22, 2013102
NCT00594347Streptococcus Pneumoniae · Thailand3CompletedSanofiMar 2008339
NCT00535730Herpes Zoster3CompletedMerckFeb 2008473
NCT00496093Pneumococcal Infections3CompletedMerckJan 2006133
NCT00368186Pneumococcal Infections · France4TerminatedPfizer51
NCT00307008Pneumonia · Sweden2CompletedGlaxoSmithKlineFeb 20051,198

How it is read

Names in the registry

  • “PPV23”, 3 entries
  • “23-valent pneumococcal polysaccharide vaccine”, 3 entries
  • “Pneumovax™ 23”, 3 entries
  • “Pneumo 23”, 2 entries
  • “23-valent Pneumococcal Polysaccharide Vaccine (PPV23)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.